RxDoctor Payments Data

David Jacks, MD

Urology · Pine Bluff, ARNPI 1093735110

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $111,000 of the $125,169 with a category attached, or 88.7%. Cryo Specialty Medical, LLC accounts for 99.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $38,296 and has fallen 99.9% since, to $27 in 2025.

$125,169in general payments, 2019–2025

Across 31 payments — averaging $4037.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cryo Specialty Medical, LLC$125K
  • Pfizer$135
  • Boston Scientific$109
  • Comsort, Inc$100
  • Myriad Genetic Laboratories, Inc.$87
  • Ferring Pharmaceuticals Inc.$54
  • plus $145 from 6 others

What the payments were for

  • Consulting fees$1000%
  • Speaking & faculty fees$13,50011%
  • Food & beverage$5550%
  • Education$140%
  • Ownership interest$111,00089%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,169 in reported general payments places this provider in the 85th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$6,933
Medicare patients
27
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate17$101,580
MyrbetriqMirabegron15$13,090
Tamsulosin Hcl550$7,951
Dutasteride205$5,507
Silodosin37$3,432
Finasteride276$2,721
Estradiol16$1,586
Trimethoprim16$901
Doxycycline Hyclate22$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$42$13,09015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 urology providers in Arkansas.

Other urology in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →